Side-effects, structure, and H2-receptor antagonists

Bossi, A. Maccabruni G.; Romeo, Giancarlo; Pezzoli, A

doi:10.1016/0140-6736(92)92023-9

Cited by 24 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have summarized the literature published to date (Table 2). All of the cross-reactions were between famotidine and ranitidine or nizatidine, but none with cimetidine 1,9,12,13. This may be due to the differences between cimetidine and other H 2 -receptor antagonists in terms of their side chain and ring structures.…”

Section: Discussionmentioning

confidence: 91%

“…Ranitidine, nizatidine, and famotidine, but not cimetidine, share similar side chains on the ring structures (Figure). 12,13 This may explain the rarity of cross-reactions of cimetidine with other H 2 -receptor antagonists. To our knowledge, this is the first report of possible cross-reactivity of cimetidine with another H 2 -receptor antagonist.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Two Cases of H₂-Receptor Antagonist Hypersensitivity and Cross-Reactivity

Song

Kim

Lee

et al. 2011

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

H2-receptor antagonists, such as cimetidine, ranitidine and famotidine, are some of the most commonly prescribed medications for gastric acid-related disorders. These compounds are generally well-tolerated and anaphylactic reactions to them are rare. Here, we report two cases of H2-receptor antagonist-induced anaphylactic reactions: the first presented with sudden dyspnea, sneezing, urticaria, and swelling of the eyelids after ranitidine intake. The second presented with sudden severe urticaria, facial swelling, chest discomfort, dizziness, and hypotension. Possible cross-reactivity with other H2-receptor antagonists was assessed by oral challenge and skin tests. To date, only a few reports addressing cross-reactivity among H2-receptor antagonists have been published. We review the literature and summarize the data available on drug cross-reactivity in H2-receptor antagonist hypersensitivity.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Two Cases of H₂-Receptor Antagonist Hypersensitivity and Cross-Reactivity

Song

Kim

Lee

et al. 2011

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

show abstract

“…In clinical practice, other studies have shown that antiH2-related side effects like hypotension and bradycardia pro arrhythmogenic with coronary ischemia risk [14]. Along with this, some cases report anaphylactic reaction with antiH2, especially ranitidine [15,16], and a retrospective observational Japanese study reports increasing risk of hand-foot syndrome and facial erythema in breast cancer patients receiving docetaxel and antiH2 as premedication [17]. Moreover, Berger et al shows in two retrospectives studies in a breast cancer population that discontinuation of premedications prior to paclitaxel administration beyond the second dose (in the case of no previous HSR) is safe and not associated with increased rate of rescue medications use [18,19].…”

mentioning

confidence: 99%

Is antihistaminergic H2 really useful in prevention of hypersensitivity induced by paclitaxel?

Slimano

Coliat

Perotin³

et al. 2016

Support Care Cancer

View full text Add to dashboard Cite

Worldwide drug shortages are a recent and growing concern which involves all drug classes, including antineoplastic [1]. Successive shortages disrupt and disorganize the activity of oncology practitioners who must find adaptive solutions [2]. Drug shortage can also impact the management of patients with cancer, with potential consequences in term of overall survival [3]. However and interestingly, successive drug shortages have refocused oncology specialists on evidence-based medicine (EBM) [4]. For example, folate shortage has pushed oncology practitioners to experiment a standardized low dose protocol, and first results appear to be consistent with a similar efficacy [5]. After the discovery of paclitaxel as an antimitotic drug, the first clinical trials with paclitaxel have revealed a high rate of HSR (up to 40 %) [7]. Clinical observations have linked this HSR with those observed with radiocontrast Media (RCM), which appears to be, at least in part, histaminergic [7]. Trial investigators and the National Cancer Institute have transposed premedication for RCM for clinical trials with paclitaxel (association of a corticoid, antiH1, and antiH2). This was followed by a significant decrease of HSR (around 1 %).Histaminergic receptors are present ubiquitously and divided according to subtypes. While H1 receptors are preferentially involved in bronchoconstriction and edema mechanisms, H2 receptors are mostly involved in gastric acid secretion. They are also involved in bronchodilation and possibly in hypotension phenomenon. Whereas role of H1 in HSR mediated by histamine is clearly demonstrated, implication of H2 receptors in HSR mediated by histamine is debated. Recent in vivo data based on a gene knockout approach suggest that both H1 and H2 take part in anaphylaxis [8]. A clinical study shows in 12 healthy or

show abstract

“…The Famotidine H 2 receptor antagonist is presently in use for the treatment of gastrointestinal ulcer and hypersecretory syndrome in numerous places throughout the world, including Japan. The use of this agent, however, has recently been reported to be complicated by erythema multiforme (1) and papuloerythematous eruptions (2). This paper presents a 69‐year‐old glioblastoma patient with unusual erythemas with extensive eosinophilia in the peripheral blood and lesional skin caused by H 2 ‐blocker famotidine (Gaster®, Yamanouchi Pharmaceutical Ltd., Japan).…”

Section: To the Editormentioning

confidence: 99%